Subscribe to our Newsletters !!
Dulbecco’s Modified Eagle Medium is perhaps the
Fetal Bovine Serum (FBS) holds great value in cell
The human metapneumovirus, more simply referred to
We are truly honored to share that HiMedia Laborat
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Dear Readers, Welcome to the latest issue of Mi
Mumbai, India, February 7, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tadalafil Tablets 20mg from the United States Food and Drug Administration (US FDA).
Cipla’s Tadalafil Tablets 20mg is AB-rated generic therapeutic equivalent version of Eli Lilly & Co.’s Adcirca ®. It is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. According to IQVIA (IMS Health), Adcirca® and its generic equivalents had US sales of approximately $490M for the 12-month period ending November 2018. The product is available for shipping immediately.
For queries, please contact:
Corporate Communications
Heena Kanal
E-Mail: [email protected]
Investor Relations
Naveen Bansal